Novaliq

Novaliq GmbH is a Heidelberg based specialty pharmaceutical company focused on ophthalmology.

Founded in 2007, Novaliq GmbH is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. The company’s most advanced products are NovaTears with CE-approval marketed under the brand name EvoTears in Europe, and NovaTears+Omega-3, which was just recently CE-approved in Europe. CyclASol, a second-generation prescription drug, is currently in pivotal phase of clinical development.